
Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

FDFT1 Reduces Stemness and Autocrine/Juxtacrine Signaling in FOLFOX-resistant Colon Cancer Cells
Vol 38, Issue 3, 2024
Abstract
Background: Colon cancer (CC) is a prevalent malignant tumor, that is widely treated with chemotherapy drug, such as 5-fluorouracil+oxaliplatin (FOLFOX). However, the emergence of FOLFOX resistance poses a significant challenge to its therapeutic efficacy. This study aimed to investigate the effect of farnesyl-diphosphate farnesyltransferase (FDFT1) on the progression of FOLFOX-resistant CC cells. Methods: The human CC cells, including HCT-116 and HT-29, were used in establishing a chemotherapy-resistant cell model by their exposure to FOLFOX. Furthermore, these cells were transfected with either FDFT1-overexpression plasmid or empty vector. The impact of FDFT1 expression on the FOLFOX-resistant CC cells was evaluated by assessing the levels of cancer stem cell markers using real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) and western blot analysis. Furthermore, the colony formation and the DNA damage/condensation were examined employing the colony forming assay and 4′,6-diamidino-2-phenylindole (DAPI) nuclei staining method, respectively. Moreover, western blot analysis was used to determine the levels of chemotherapy-resistance-related proteins, cell proliferation-related epidermal growth factor receptor (EGFR), and autocrine/juxtacrine pathway-related transforming growth factor alpha (TGF-α). Finally, the apoptosis rate in the transfected cells was assessed utilizing terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and flow cytometry. Results: The FDFT1 was downregulated in FOLFOX-resistant cells (p < 0.01) and cell transfection successfully upregulated FDFT1 in FOLFOX-resistant cells (p < 0.01). Furthermore, FDFT1 overexpression substantially reduced cancer stem cell markers (p < 0.01), inhibited tumor sphere formation (p < 0.01), increased DNA condensation (p < 0.001), and suppressed drug-related proteins (p < 0.001) in FOLFOX-resistant cells. Moreover, overexpression of FDFT1 suppressed the cell proliferation and reduced the activity of autocrine/juxtacrine signaling in FOLFOX-resistant cells by downregulating EGFR (p < 0.001) and TGF-α (p < 0.001). Additionally, FDFT1 increased apoptosis in FOLFOX-resistant cells when exposed to FOLFOX (p < 0.01). Conclusion: This study revealed an inhibitory role of FDFT1 in FOLFOX-resistant CC cells. Overexpression of FDFT1 can reduce cancer stem cell markers and inhibit tumor proliferation. Additionally, overexpression of FDFT1 suppressed the activity of autocrine/juxtacrine signaling, leading to increased cell apoptosis. These findings suggest FDFT1 as a potential therapeutic target and offer new insights for improving the efficacy of FOLFOX.
Keywords
References
Supporting Agencies
Copyright (c) 2024 Shanyu Gao, Xiaoming Liu, Congcong Liu, Lin Guo, Liwei Yan, Chunhua Chi, Jiulian Liu, Jiaxin Dong, Dingwei Zhen, Tong Liu
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Medical Genetics, University of Torino Medical School, Italy

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy